Strategies to meet the need for long-term data

Journal of Hypertension

Volumn 34, Issue 8, 2016, Pages 1473-1479

  Chalmers, John ^a   Woodward, Mark ^a,b,c   Borghi, Claudio ^d   Manolis, Athanasios ^e   Mancia, Giuseppe ^f,g  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e Asklepeion Hospital   (Greece)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

^g ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

administrative database; cohort study; cost effectiveness study; database; long term follow up; randomized controlled trial; registry

Indexed keywords

COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ELECTRONIC HEALTH RECORD; FOLLOW UP; HUMAN; LONG TERM CARE; LONG TERM EXPOSURE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; COST BENEFIT ANALYSIS; FACTUAL DATABASE; INFORMATION PROCESSING; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER;

COST-BENEFIT ANALYSIS; DATA COLLECTION; DATABASES, FACTUAL; FOLLOW-UP STUDIES; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES;

EID: 84973351694     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000987     Document Type: Review

References (55)

1. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520.
2. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
3. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32:3-15.
4. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine. Clinical practice guidelines we can trust. Washington, DC: The National Academies Press 2011.
5. Diabetes Control, Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-853.
7. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
8. DCCT/EDIC Research Groupde Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. . Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365:2366-2376.
9. Holman R, Paul S, Bethel MA, Matthews D, Neil A. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 9:1577-1589.
10. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, et al. Followup of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371:1392-1406.
11. Hayward RA, Reaven PD, Emanuele NV, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373:978.
12. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.
13. Kostis WJ, Thijs L, Richart T, Kostis JB, Staessen JA. Persistence of mortality reduction after the end of randomised therapy in clinical trials of BP lowering medications. Hypertension 2010; 56:1060-1068.
14. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-Term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359:1565-1576.
15. Appel LJ, Wright JT Jr, Green T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363:918-929.
16. Brouwers FP, Asselbergs FW, Hillege HL, De Boer RA, Gansevoort RT, Van Veldhuisen DJ, et al Long-Term Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects with Microalbuminuria: Ten Years of Follow-up of Prevention of Renal and Vascular End-Stage Disease Intervention Trial (PREVEND IT). Am Heart J 2011 161 1171-1171.
17. Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to hypertension in the very elderly randomised controlled trial. BMJ 2011; 344:d7541.
18. Simes J, Simes RJ, Hunt D, Kirby A, Tonkin A, Keech A, et al. Long-Term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet 2002; 359:1379-1387.
19. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, et al Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364:771-777
20. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR, ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J 2011; 32:2525-2532.
21. Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet 2011; 378:2013-2020.
22. Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, et al Long-Term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). J Clin Hypertens 2013; 15:542-554
23. Beckett N, Peters R, Fletcher A, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years or older. N Engl J Med 2008; 358:1887-1898.
24. Ivers RQ, Blows SJ, Stevenson MR, Norton RN, Williamson A, Eisenbruch M, et al. A cohort study of 20 822 young drivers: the DRIVE study methods and population. Injury Prev 2006; 12:385-389.
25. Land MA, Webster J, Christoforou A, Praveen D, Jeffery P, Chalmers J, et al. Salt intake assessed by 24 h urinary sodium excretion in a random and opportunistic sample in Australia. BMJ Open 2014; 4:e003720.
26. Tunstall-Pedoe H, Woodward M, Tavendale R, A?Brook R, McCluskey MK. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study. BMJ 1997; 315:722-729.
27. Tunstall-Pedoe H, Woodward M, Hughes M, Anderson A, Kennedy G, Belch J, Kuulasmaa K Prime mover or fellow traveller: 25-hydroxy vitamin D?s seasonal variation, cardiovascular disease and death in the Scottish Heart Health Extended Cohort (SHHEC). Int J Epidemiol 2015; 44:1602-1612
28. https://www.framinghamheartstudy.org/. [Accessed 9 September 2015]
29. https://www2.cscc.unc.edu/aric/. [Accessed 9 September 2015]
30. Vathesatogkit P, Woodward M, Tanomsup S, Ratanachaiwong W, Vanavanan S, Yamwong S, Sritara P. Cohort profile: the Electricity Generating Authority of Thailand study. Int J Epidemiol 2012; 41:359-365.
31. http://www.bristol.ac.uk/alspac/. [Accessed 9 September 2015]
32. http://www.ckbiobank.org/site/. [Accessed 9 September 2015]
33. http://www.ukbiobank.ac.uk/. [Accessed 29 March 2016]
34. AchesonED, Evans JG. TheOxfordRecord Linkage Study: a reviewof the method with somepreliminary results. Proc R SocMed 1964; 57:269-274.
35. http://www.cprd.com/intro.asp. [Accessed 9 September 2015]
36. Bates DW, Saria S, Ohno-Machado L, Shah A, Escobar G. Big data in healthcare: using analytics to identify and manage high-risk and highcost patients. Health Aff (Millwood) 2014; 33:1123-1131.
37. Emdin CA, Anderson SG, Woodward M, Rahimi K. Usual blood pressure and risk of new onset diabetes: evidence from 4.1 million adults and a meta-Analysis of prospective studies. JACC 2015; 66:1552-1562.
38. Corrao G, Mancia G. Generating evidence from computerized healthcare utilization databases. Hypertension 2015; 65:490-498.
39. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, Mancia G. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29:610-618.
40. Corrao G, Conti V, Merlino L, Catapano A, Mancia G. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Clin Ther 2010; 32:300-310.
41. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007; 335:136.
42. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 2011; 30:377-399.
43. Williamson E, Morley R, Lucas A, Carpenter J. Propensity scores: from naive enthusiasm to intuitive understanding. Stat Methods Med Res 2012; 21:273-293.
44. Kostkova P, Brewer H, de Lusignan S, Fottrell E, Goldacre B, Hart G, et al. Who owns the data? Open data for healthcare. Front Public Health 2016; 4:7.
45. Williams G, Pigeot I. Consent and confidentiality in the light of recent demands for data sharing. Biom J 2016; doi:10.1002/bimj.201500044.
46. Lauer MS, D'Agostino RB Sr The randomized registry trial: The next disruptive technology in clinical research? N Engl J Med 2013; 369:1579-1581
47. Frobert O, Lagergvist B, Olivecrona G, Omerovic E, Gudnason T, Maeng M, et al. Thrombus aspiration during ST-Segment elevation myocardial infarction. N Engl J Med 2013; 369:1587-1597.
48. Jernberg T, Attebring MF, Hambraeus K, et al The Swedish Web system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). Heart 2010; 96:1617-1621
49. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-Term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477-1486.
50. Angus DC Fusing randomized trials with big data: The key to selflearning healthcare systems? JAMA 2015; 314:767-768
51. Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care 2005; 43 (7 Suppl):5-14.
52. Elliott WG, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-Analysis. Lancet 2007; 369:201-207.
53. Corrao G, Ibrahim B, Nicotra F, Soranna D, Merlino L, Catapano AL, et al. Statins and the risk of diabetes: evidence from a large populationbased cohort study. Diabetes Care 2014; 37:2225-2232.
54. Riley GF. Administrative and claims record as sources of healthcare cost data. Med Care 2009; 47 (7 Suppl. 1):S51-S55.
55. Pearson SA, Pesa N, Langton JM, et al Studies Using Australia?s Pharmaceutical Benefits Scheme Data for Pharmacoepidemiological Research: A Systematic Review of the Published Literature (1987-2013). Pharmacoepidemiol Drug Saf 2015 24 447-447.